212 results on '"Gu, Haihua"'
Search Results
202. Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer.
- Author
-
Li L, Cao J, Chen C, Qin Y, He L, Gu H, and Wu G
- Abstract
Breast cancer is the most common malignant cancer in women. Triple-negative breast cancer (TNBC) has a poorer prognosis than other subtypes and is challenging to treat. MUC1 is a therapeutic target in breast and pancreatic cancer. We developed a novel humanized antibody that specifically binds MUC1 expressed in breast cancer cells and conjugated a humanized MUC1 (HzMUC1) antibody to monomethyl auristatin (MMAE). HzMUC1-MMAE showed an anti-proliferative effect on HER2 positive trastuzumab-resistant breast cancer. Immunoprecipitation indicated that HzMUC1 recognized native MUC1 in TNBC cells. Confocal microscopy showed that HzMUC1 bound MUC1 on the surface of TNBC cells, and the conjugates exhibited the same binding ability to HCC70 as unconjugated HzMUC1 by cell-based ELISA. Treatment of TNBC cells with HzMUC1-MMAE reduced growth of MUC1-positive cells and induced G2/M cell cycle arrest and apoptosis. In a mouse model of breast cancer, HzMUC1-MMAE significantly reduced the growth of tumors established by subcutaneous injection of HCC70 TNBC cells. Therefore, HzMUC1-ADC has therapeutic potential for TNBC., Competing Interests: The authors declare no conflict of interest., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
203. Zoledronic acid induces ferroptosis by reducing ubiquinone and promoting HMOX1 expression in osteosarcoma cells.
- Author
-
Ren T, Huang J, Sun W, Wang G, Wu Y, Jiang Z, Lv Y, Wu G, Cao J, Liu M, and Gu H
- Abstract
Aims: Ferroptosis plays important roles in tumorigenesis and cancer therapy. Zoledronic acid is known to inhibit the activity of farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway. We examined whether zoledronic acid can inhibit the growth of osteosarcoma cells by inducing ferroptosis. Methods : Cell viability was analyzed by using CCK8 reagent and counting cells with trypan blue exclusion. Ferroptosis markers including lipid peroxide and PTGS2 expression were examined by flow cytometry, western blot, and quantitative PCR analyses. Cellular ubiquinone content was determined using high performance liquid chromatography. Ferrostatin-1 and RSL3 were used as the ferroptosis inhibitor and inducer respectively. Results : Zoledronic acid treatment decreased cell viability and promoted the increase in lipid peroxide content and PTGS2 expression. Addition of ferrostatin-1 reverted these effects of zoledronic acid on osteosarcoma cells, supporting a role of zoledronic acid in inducing ferroptosis. Mechanistically, zoledronic acid significantly decreased ubiquinone, a metabolite of the mevalonate pathway. Treating cells with exogenous ubiquinone prevented zoledronic acid-induced ferroptosis and decrease in the growth of osteosarcoma cells. In addition, zoledronic acid enhanced the expression of HMOX1, whereas knockdown of HMOX1 inhibited the zoledronic acid-induced increase in lipid peroxide level and decrease in cell growth. Finally, zoledronic acid together with RSL3 significantly enhanced the inhibitory effect on the growth of osteosarcoma cells. Conclusion: Our results indicate that zoledronic acid induces ferroptosis by decreasing ubiquinone content and promoting HMOX1 expression in osteosarcoma cells. Zoledronic acid together with ferroptosis inducer may be a promising new strategy for the treatment of osteosarcoma., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Ren, Huang, Sun, Wang, Wu, Jiang, Lv, Wu, Cao, Liu and Gu.)
- Published
- 2023
- Full Text
- View/download PDF
204. The influence of 10-year Nuss bar placement on bar removal: a case report.
- Author
-
Gu H, Xu G, Liu T, and Zhang S
- Subjects
- Humans, Male, Young Adult, Adult, Retrospective Studies, Sternum surgery, Mediastinum, Tomography, X-Ray Computed, Minimally Invasive Surgical Procedures methods, Treatment Outcome, Funnel Chest surgery
- Abstract
Background: The Nuss bar is commonly used for minimally invasive correction of pectus excavatum and is usually removed within 2-3 years. Here, we report a case of 10-year bar placement after the Nuss procedure accompanied by unique complications of thoracic malformation that have not been described before. The asymmetric pectus carinatum caused by bar displacement and significant rib periosteal hyperplasia is described for the first time., Case Presentation: A 23-year-old man was admitted to our hospital due to the main complaint of obvious chest discomfort when lifting heavy weights. The bar removal was seriously delayed due to his loss to follow-up. Chest asymmetry and distant heart sounds were found during a physical examination. A chest CT scan demonstrated that the right end of the lower bar originally fixed outside the ribs had shifted into the thoracic cavity, and the left costal cartilage was obviously protruding. Additionally, the displaced bars were separated from the sternum and tightly attached to the pericardium, resulting in abnormalities of the anterior mediastinum. These secondary thoracic deformities made the patient extremely prone to massive hemorrhage or multiple rib fractures when sliding the bars out. However, serious consequences were avoided due to reasonable adjustments to the usual bar removal procedures., Conclusion: This case demonstrates a specific type of bar displacement caused by prolonged placement of the bars and highlights the importance of rigorous follow-up of patients after the Nuss procedure., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
205. Gab2 promotes acute myeloid leukemia growth and migration through the SHP2-Erk-CREB signaling pathway.
- Author
-
Gong R, Li H, Liu Y, Wang Y, Ge L, Shi L, Wu G, Lyu J, Gu H, and He L
- Subjects
- Adaptor Proteins, Signal Transducing, Aged, Humans, Matrix Metalloproteinase 9, RNA, Small Interfering genetics, Signal Transduction, Leukemia, Myeloid, Acute genetics, Matrix Metalloproteinase 2
- Abstract
Acute myeloid leukemia (AML) is a hematologic malignant disease largely affecting older adults with poor outcomes. Lack of effective targeted treatment is a major challenge in managing the disease in the clinic. Scaffolding adaptor Gab2 is amplified in a subset of AML. However, the causative role of Gab2 in AML remains to be explored. In this study, it was found that Gab2 was expressed at high levels in AML patient samples and AML cell lines. Experiments by knocking down Gab2 expression using shRNA showed that Gab2 promoted AML cell growth and migration in vitro and in vivo. Further studies using Gab2 mutants and pharmacological inhibitors revealed that Gab2 increased CREB phosphorylation via the SHP-2/Erk signaling pathway. CREB phosphorylation contributed to Gab2-induced cell migration by increasing MMP2 and MMP9 expression. This research indicates that high Gab2 expression promotes AML progression through the SHP2-Erk-CREB signaling pathway. CREB suppression may help treat AML with high Gab2 expression., (©2022 Society for Leukocyte Biology.)
- Published
- 2022
- Full Text
- View/download PDF
206. Erratum: Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade.
- Author
-
Li H, Yuan W, Bin S, Wu G, Li P, Liu M, Yang J, Li X, Yang K, and Gu H
- Abstract
[This corrects the article on p. 688 in vol. 10, PMID: 32195036.]., (AJCR Copyright © 2022.)
- Published
- 2022
207. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
- Author
-
Wu G, Li L, Qiu Y, Sun W, Ren T, Lv Y, Liu M, Wang X, Tao H, Zhao L, Cao J, He L, Li H, and Gu H
- Subjects
- Animals, Antibodies, Monoclonal, Humanized metabolism, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents, Immunological metabolism, Antineoplastic Agents, Immunological therapeutic use, Apoptosis drug effects, Breast Neoplasms blood, Breast Neoplasms pathology, Cell Cycle Checkpoints drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Drug Resistance, Neoplasm immunology, Epitopes, Humans, Immunoconjugates therapeutic use, Mice, Mice, Inbred BALB C, Mice, Nude, Mucin-1 blood, Mucin-1 chemistry, Mucin-1 immunology, Oligopeptides chemistry, Oligopeptides pharmacology, Oligopeptides therapeutic use, Receptor, ErbB-2 immunology, Receptor, ErbB-2 metabolism, Xenograft Model Antitumor Assays, Antibodies, Monoclonal, Humanized pharmacology, Antineoplastic Agents, Immunological pharmacology, Breast Neoplasms drug therapy, Drug Resistance, Neoplasm drug effects, Immunoconjugates pharmacology, Mucin-1 metabolism, Trastuzumab pharmacology
- Abstract
Mucin 1 (MUC1) has been regarded as an ideal target for cancer treatment, since it is overexpressed in a variety of different cancers including the majority of breast cancer. However, there are still no approved monoclonal antibody drugs targeting MUC1. In this study, we generated a humanized MUC1 (HzMUC1) antibody from our previously developed MUC1 mouse monoclonal antibody that only recognizes MUC1 on the surface of tumor cells. Furthermore, an antibody-drug conjugate (ADC) was generated by conjugating HzMUC1 with monomethyl auristatin (MMAE), and the efficacy of HzMUC1-MMAE on the MUC1-positive HER2+ breast cancer in vitro and in 'Xenograft' model was tested. Results from western blot analysis and immunoprecipitation revealed that the HzMUC1 antibody did not recognize cell-free MUC1-N in sera from breast cancer patients. Confocal microscopy analysis showed that HzMUC1 antibody bound to MUC1 on the surface of breast cancer cells. Results from mapping experiments suggested that HzMUC1 may recognize an epitope present in the interaction region between MUC1-N and MUC1-C. Results from colony formation assay and flow cytometry demonstrated that HzMUC1-MMAE significantly inhibited cell growth by inducing G2/M cell cycle arrest and apoptosis in trastuzumab-resistant HER2-positive breast cancer cells. Meanwhile, HzMUC1-MMAE significantly reduced the growth of HCC1954 xenograft tumors by inhibiting cell proliferation and enhancing cell death. In conclusion, our results indicate that HzMUC1-ADC is a novel therapeutic drug that can overcome trastuzumab resistance of breast cancer. HzMUC1-ADC should also be an effective therapeutic drug for the treatment of different MUC1-positive cancers in clinic., (© The Author(s) 2021. Published by Oxford University Press on behalf of the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
208. USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor α.
- Author
-
Cao J, Wu D, Wu G, Wang Y, Ren T, Wang Y, Lv Y, Sun W, Wang J, Qian C, He L, Yang K, Li H, and Gu H
- Subjects
- Animals, Breast Neoplasms metabolism, Breast Neoplasms pathology, Carcinogenesis drug effects, Carcinogenesis genetics, Carcinogenesis metabolism, Endopeptidases genetics, Estrogen Receptor alpha drug effects, Estrogen Receptor alpha metabolism, Female, Gene Expression Regulation, Neoplastic drug effects, HEK293 Cells, Humans, MCF-7 Cells, Mice, Protein Processing, Post-Translational drug effects, Protein Stability drug effects, Proto-Oncogene Proteins c-akt metabolism, Signal Transduction drug effects, Tumor Cells, Cultured, Breast Neoplasms genetics, Endopeptidases physiology, Estradiol pharmacology, Estrogen Receptor alpha genetics
- Abstract
Although endocrine therapies targeting estrogen receptor α (ERα) are effective in managing ER positive (+) breast cancer, many patients have primary resistance or develop resistance to endocrine therapies. In addition, ER+ breast cancer with PIK3CA activating mutations and 11q13-14 amplification have poor survival with unclear mechanism. We uncovered that higher expression of deubiquitinase USP35, located in 11q14.1, was associated with ER+ breast cancer and poor survival. Estrogen enhanced USP35 protein levels by downregulating USP35-targeting miRNA-140-3p and miRNA-26a-5p. USP35 promoted the growth of ER+ breast cancer in vitro and in vivo, and reduced the sensitivity of ER+ breast cancer cells to endocrine therapies such as tamoxifen and fulvestrant. Mechanistically, USP35 enhanced ERα stability by interacting and deubiquitinating ERα, and transcriptional activity of ERα by interacting with ERα in DNA regions containing estrogen response element. In addition, AKT, a key effector of PI3K, phosphorylated USP35 at Serine613, which promoted USP35 nuclear translocation, ERα transcriptional activity, and the growth of ER+ breast cancer cells. Our data indicate that USP35 and ERα form a positive feedback loop in promoting the growth of ER+ breast cancer. USP35 may be a treatment target for ER+ breast cancer with endocrine resistance or with PIK3CA mutations or hyperactivation of the PI3K pathway.
- Published
- 2021
- Full Text
- View/download PDF
209. PRRG4 promotes breast cancer metastasis through the recruitment of NEDD4 and downregulation of Robo1.
- Author
-
Zhang L, Qin Y, Wu G, Wang J, Cao J, Wang Y, Wu D, Yang K, Zhao Z, He L, Lyu J, Li H, and Gu H
- Subjects
- Amino Acid Motifs, Animals, Cell Line, Tumor, Cell Movement, Cell Transformation, Neoplastic, Enzyme Activation, Focal Adhesion Kinase 1 metabolism, Gene Expression Regulation, Neoplastic, Membrane Proteins chemistry, Membrane Proteins genetics, Mice, Neoplasm Invasiveness, Neoplasm Metastasis, RNA, Messenger genetics, Roundabout Proteins, Breast Neoplasms pathology, Down-Regulation, Membrane Proteins metabolism, Nedd4 Ubiquitin Protein Ligases metabolism, Nerve Tissue Proteins metabolism, Receptors, Immunologic metabolism
- Abstract
Metastasis is responsible for the death of most breast cancer patients. Robo1 has been implicated as a tumor suppressor for various cancers including breast cancer. However, it is not well understood how Robo1 expression is regulated during tumorigenesis. In this study, we uncovered that the transmembrane proline rich γ-carboxyglutamic acid protein 4 (PRRG4) promotes breast cancer metastasis by downregulating Robo1. Analysis of mRNA expression data in The Cancer Genome Atlas and immunohistochemistry assay on breast tumor samples showed that PRRG4 expression was higher in breast tumors than in normal breast tissues. Experiments with PRRG4 knockdown and overexpression revealed that PRRG4 promoted migration and invasion of breast cancer cells, and enhanced metastasis in an experimental metastasis model. Mechanistically, we found that PRRG4 via its LPSY and PPPY motifs recruited the E3 ubiquitin ligase NEDD4, which induced ubiquitination and degradation of Robo1, thus contributing to migration and invasion of breast cancer cells. In addition, PRRG4 interacted with and enhanced protein tyrosine kinase Src and FAK activation. Overall, our data support a model that PRRG4 via NEDD4 downregulates the Robo1, resulting in the activation of Src and FAK and promoting breast cancer metastasis. PRRG4 may be a novel target for treating metastatic breast cancer.
- Published
- 2020
- Full Text
- View/download PDF
210. Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade.
- Author
-
Li H, Yuan W, Bin S, Wu G, Li P, Liu M, Yang J, Li X, Yang K, and Gu H
- Abstract
Trastuzumab-resistance is still a major challenge in treating patients with HER2 positive breast cancer. In this study, we tried to overcome transtuzumab-resistance by examining the therapeutic efficacy of third generation anti-HER2 chimeric antigen receptor (CAR)-T cells alone and in combination with PD1 blockade against HER2 positive and trastuzumab-resistance breast cancer cells in vitro and xenograft model. The anti-HER2 CAR-T cells were generated by infecting CD3/CD28 activated peripheral blood mononuclear cells with lentivirus expressing third generation anti-HER2 CAR. Anti-HER2 CAR-T cells were specifically targeted to HER2 positive BT474 and trastuzumab resistant HCC1954 cells compared with HER2 negative breast cancer cells. Results from ELISA revealed that the secretion of IL-2 and IFN-γ was increased in anti-HER2 CAR-T cells after being co-cultured with HCC1954 cells, and was further increased with the addition of anti-PD1 antibody in the co-culture system. Furthermore, data from lactate dehydrogenase assay showed that anti-HER2 CAR-T cells displayed a potent cytotoxicity against HCC1954 and BT474 cells. Addition of anti-PD1 antibody further enhanced the cytotoxicity of anti-HER2 CAR-T cells against HCC1954 cells. Lastly, injection of anti-HER2 CAR-T cells significantly reduced the growth of HCC1954 xenograft tumors. Combining anti-HER2 CAR-T cells with anti-PD1 antibody further impaired the growth of HCC1954 tumors. The present results indicate that anti-HER2 CAR-T cells have therapeutic efficacy against trastuzumab resistant breast tumors and addition of the PD1 antibody can further enhance the therapeutic effect of anti-HER2 CAR-T cells. Thus, third generation anti-HER2 CAR-T cells along with PD1 blockade is a potential therapy to overcome trastuzumab resistance of breast cancer., Competing Interests: None., (AJCR Copyright © 2020.)
- Published
- 2020
211. A study of maternal hemodynamic change during healthy pregnancy and women with gestation hypertension.
- Author
-
Gu H, Zhang S, Qiao Y, Luo Z, Zeng Y, and Wang Q
- Subjects
- Blood Flow Velocity, Female, Humans, Pregnancy, Reproducibility of Results, Sensitivity and Specificity, Statistics as Topic, Vascular Resistance, Algorithms, Blood Pressure, Cardiac Output, Diagnosis, Computer-Assisted methods, Heart Rate, Hypertension, Pregnancy-Induced diagnosis, Hypertension, Pregnancy-Induced physiopathology
- Abstract
Objective: To investigate the maternal hemodynamic changes that occurs during pregnancy. To find out the difference that lie in healthy pregnancy and women with gestational hypertension. To introduce a method that is applied to shift high-risk women of gestational hypertension in pregnancy women., Method: Serial hemodynamic investigations (total 8 times) were performed throughout pregnancy period by radioulnar pulse wave electrical monitoring in 182 women (130 with healthy pregnancies, 52 with gestational hypertension). Analysis of variance with repeated measurements was used to evaluate the course of a number of hemodynamic indices. To identify the correlation between these changes and gestational hypertension by using above method., Results: A significant difference in mean arterial pressure (MAP), cardiac output (CO), cardiac index (CI), total Peripheral Resistance (TPR) and heart rat (HR) was observed different between normal pregnancy and women with gestational hypertension. The changes of parameters in normal woman and gestational hypertension were recorded and the mechanism of gestational hypertension was heterogenous., Conclusion: These results provide sensitive parameters for use in early risk assessment and as a guide to preventive intervention during pregnancy.
- Published
- 2006
212. Critical role for scaffolding adapter Gab2 in Fc gamma R-mediated phagocytosis.
- Author
-
Gu H, Botelho RJ, Yu M, Grinstein S, and Neel BG
- Subjects
- Adaptor Proteins, Signal Transducing, Animals, Binding Sites drug effects, Binding Sites physiology, Cell Line, Enzyme Inhibitors pharmacology, Intracellular Signaling Peptides and Proteins, Mice, Phosphatidylinositol 3-Kinases metabolism, Protein Structure, Tertiary drug effects, Protein Structure, Tertiary physiology, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Protein Tyrosine Phosphatases metabolism, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins c-akt, Signal Transduction physiology, Cell Membrane metabolism, Macrophages metabolism, Phagocytosis physiology, Phagosomes metabolism, Phosphoproteins metabolism, Protein Serine-Threonine Kinases, Receptors, Fc metabolism, Receptors, IgG
- Abstract
Grb2-associated binder 2 (Gab2), a member of the Dos/Gab subfamily scaffolding molecules, plays important roles in regulating the growth, differentiation, and function of many hematopoietic cell types. In this paper, we reveal a novel function of Gab2 in Fcgamma receptor (FcgammaR)-initiated phagocytosis in macrophages. Upon FcgammaR activation, Gab2 becomes tyrosyl phosphorylated and associated with p85, the regulatory subunit of phosphoinositide 3-kinase (PI3K), and the protein-tyrosine phosphatidylinositol Shp-2. FcgammaR-mediated phagocytosis is severely impaired in bone marrow-derived macrophages from Gab2-/- mice. The defect in phagocytosis correlates with decreased FcgammaR-evoked activation of Akt, a downstream target of PI3K. Using confocal fluorescence microscopy, we find that Gab2 is recruited to the nascent phagosome, where de novo PI3K lipid production occurs. Gab2 recruitment requires the pleckstrin homology domain of Gab2 and is sensitive to treatment with the PI3K inhibitor wortmannin. The Grb2 binding site on Gab2 also plays an auxiliary role in recruitment to the phagosome. Because PI3K activity is required for FcgammaR-mediated phagocytosis, our results indicate that Gab2 acts as a key component of FcgammaR-mediated phagocytosis, most likely by amplifying PI3K signaling in the nascent phagosome.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.